Keith Stockerl-Goldstein
Overview
Explore the profile of Keith Stockerl-Goldstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou A, Marin N, Afrin S, Wong P, Tran J, Jacobs M, et al.
J Immunol
. 2025 Mar;
214(1):1-11.
PMID: 40073259
Natural killer (NK) cells are a promising approach for cellular cancer immunotherapy and are being investigated to treat patients with multiple myeloma (MM). We found that MM patient blood NK...
2.
Dimopoulos M, Voorhees P, Schjesvold F, Cohen Y, Hungria V, Sandhu I, et al.
N Engl J Med
. 2024 Dec;
PMID: 39652675
Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor...
3.
Abboud R, Schroeder M, Rettig M, Jayasinghe R, Gao F, Eisele J, et al.
Blood
. 2024 Nov;
PMID: 39576962
Haploidentical hematopoietic cell transplantation (haplo-HCT) is an increasingly used treatment for hematologic malignancies. Although post-transplant cyclophosphamide (PtCy) has improved graft vs. host disease (GvHD) prophylaxis in haplo-HCT, patients continue to...
4.
Jacoby M, Duncavage E, Khanna A, Chang G, Nonavinkere Srivatsan S, Miller C, et al.
Leukemia
. 2024 Oct;
39(1):166-177.
PMID: 39367170
Accurate assessment of therapy response in myelodysplastic neoplasm (MDS) has been challenging. Directly monitoring mutational disease burden may be useful, but is not currently included in MDS response criteria, and...
5.
A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma
Goldsmith S, Slade M, Fiala M, Harding M, Crees Z, Schroeder M, et al.
Ann Hematol
. 2024 Sep;
103(11):4557-4565.
PMID: 39227452
Introduction: Patients with triple-class refractory (TCR) multiple myeloma (MM) often need cytoreductive chemotherapy for rapid disease control. Bendamustine is an outpatient-administered, bifunctional alkylator and isatuximab is an anti-CD38 monoclonal antibody...
6.
Cheng R, Kittleson M, Wechalekar A, Alvarez-Cardona J, Mitchell J, Macedo A, et al.
Heart
. 2024 Jan;
110(12):823-830.
PMID: 38267197
The prevalence of amyloidosis has been increasing, driven by a combination of improved awareness, evolution of diagnostic pathways, and effective treatment options for both transthyretin and light chain amyloidosis. Due...
7.
Slade M, Fiala M, Kirchmeyer M, King J, Gao F, Schroeder M, et al.
Transplant Cell Ther
. 2023 Sep;
29(12):764.e1-764.e7.
PMID: 37741459
Second autologous hematopoietic cell transplantation (AHCT2) is a useful therapeutic modality for fit patients with multiple myeloma who have durable remission after upfront AHCT. Retrospective studies have suggested a significant...
8.
Xu Z, Choi J, Cooper M, King J, Fiala M, Liu J, et al.
Transplant Cell Ther
. 2023 Aug;
29(11):699.e1-699.e9.
PMID: 37597685
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic cell transplantation (allo-HCT). The hypomethylating agent azacitidine (AZA) has been shown to be effective in preclinical and clinical studies for...
9.
Loncharich A, Fiala M, Slade M, Vickroy A, Kavanaugh M, Wilson C, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Aug;
23(11):825-828.
PMID: 37543510
Background: Multiple myeloma (MM), as well as some treatments for MM, increase the risk of venous thromboembolism (VTE). Prior literature suggests carfilzomib, lenalidomide, and dexamethasone (KRd) may have a higher...
10.
Azimi V, Slade M, Fiala M, Fortier J, Stockerl-Goldstein K, Frater J, et al.
Clin Chem
. 2023 May;
PMID: 37147848
Background: Serum free light chain (sFLC) assays are interpreted using a sFLC-ratio-based reference interval (manufacturer's interval) that was defined using a cohort of healthy patients. However, renal impairment elevates the...